Astragalus polysaccharide ameliorates adipogenic skewing and dysfunction of bone marrow mesenchymal stromal cells in aplastic anemia via mTOR inhibition
Astragalus polysaccharide (APS) ameliorates the proliferation defects, apoptosis, and aberrant adipogenic differentiation of bone marrow mesenchymal stromal cells in aplastic anemia by inhibiting the mTOR pathway, thereby restoring the hematopoietic-supportive stromal niche.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, the bone marrow is a bustling factory where blood cells are constantly manufactured to keep us alive. This factory relies on a supportive neighborhood of specialized cells called mesenchymal stromal cells. Think of these cells as the foremen and construction crew that maintain the factory floor, ensuring the right conditions for blood production. In a healthy person, these foremen help create a balanced environment, guiding the factory to produce the necessary blood components. However, in a severe condition known as aplastic anemia, this entire system breaks down. The factory floor becomes damaged, the foremen stop working correctly, and the environment turns hostile. Instead of supporting blood production, the damaged cells begin to transform into fat cells, filling the marrow with useless fatty tissue and leaving the blood-making machinery starved for space and support.
Scientists have long understood that the immune system often attacks the blood-making cells in this disease, but recent research has shifted focus to the damaged neighborhood itself. If the supporting cells are broken, fixing them might be the key to restarting the factory. A traditional Chinese herb called Astragalus membranaceus has been used for centuries to support vitality, and its main active ingredient, a substance called Astragalus polysaccharide, has shown promise in various healing processes. Researchers wanted to know if this natural compound could repair the specific damage happening inside the bone marrow of patients with aplastic anemia, particularly the tendency of these support cells to turn into fat instead of helping make blood.
To find the answer, a team of researchers collected bone marrow samples from twenty-one patients who had just been diagnosed with aplastic anemia and had not yet received treatment. They carefully isolated the mesenchymal stromal cells from these samples and grew them in a laboratory setting. The team then exposed these cells to different amounts of the Astragalus polysaccharide, ranging from very small doses to quite large ones, to see how the cells would react. They treated the cells for forty-eight hours and then ran a series of tests to measure their health. They checked how well the cells multiplied, how many were dying, and whether they were stuck in a resting state or actively dividing. They also looked closely at the cells to see if they were accumulating fat, which is the hallmark of the disease's damage.
The results were clear and encouraging. When the cells were treated with the Astragalus compound, they began to thrive. The substance helped the cells multiply more effectively and significantly reduced the number of cells that were dying. In a healthy marrow, these cells move through their life cycle smoothly, but in the diseased marrow, they often get stuck in a resting phase. The treatment helped push the cells out of this stagnation, allowing them to progress into the active phases of division. Perhaps most importantly, the treatment stopped the cells from turning into fat. In the untreated samples, the cells were filled with lipid droplets, appearing as bright red spots under a microscope, but in the treated samples, these fat deposits disappeared almost entirely. The cells remained in a state that was ready to support blood production rather than becoming inert fat.
Digging deeper, the researchers investigated the internal machinery that controls these changes. They found that the cells from the patients had a specific signaling pathway, known as the mTOR pathway, that was stuck in the "on" position. This overactive signal was like a stuck accelerator, forcing the cells to stop making blood support and start turning into fat instead. The Astragalus polysaccharide acted as a regulator, slowing down this overactive signal. By reducing the activity of this pathway, the compound stopped the cells from following the wrong instructions. It lowered the levels of the specific proteins that tell a cell to become fat, effectively reprogramming the cells back to their original, helpful role. The study confirmed that this effect was dose-dependent, meaning that higher amounts of the compound produced stronger results, with a high dose of 1000 micrograms per milliliter showing the most significant improvement.
This work suggests that the damage in aplastic anemia is not just about the immune system attacking blood cells, but also about the supporting environment losing its way. The study provides evidence that a natural compound derived from Astragalus can reverse this specific type of cellular damage. By calming the overactive signals inside the cells, the treatment restores their ability to multiply and stops them from turning into fat. While the researchers note that further testing in animals is needed to confirm these effects in a living body, the findings offer a new perspective on how to treat the disease. Instead of only focusing on suppressing the immune system, this approach looks at repairing the very foundation of the bone marrow, potentially offering a way to rebuild the factory floor so that blood production can begin again.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.